Click the image for product info
| Composition: | Lenvatinib Mesylate |
| Indication: | LENVATINIB is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurtle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). LENVATINIB in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). LENVATINIB is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy. LENVATINIB is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy (see section Pharmacodynamics). LENVATINIB, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with platinum-containing therapy in any setting and are not candidates for curative surgery or radiation. |
| Packing: | 2 x 10 Capsules |
| Composition: | Pemetrexed Injection (10mg/mL) Solution for Infusion |
| Indication: | Malignant pleural mesothelioma, first line treatment of patients with locally advanced or metastatic non-small cell lung cancer. |
| Packing: | 1 x 10ml Vials 1 x 50ml Vials 1 x 100ml Vials |
| Composition: | Oxaliplatin Concentrate for Solution for Infusion 5 mg/ml |
| Indication: | Adjuvant treatment of stage III (Dukes’ C) colon cancer after complete resection of the primary tumour and treatment of metastatic colorectal cancer. |
| Packing: | 50mg / 10ml & 100mg / 20ml |
| Composition: | Docetaxel trihydrate injection (10 mg/mL) |
| Indication: | Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer, Gastric Adenocarcinoma, Head and neck cancer. |
| Packing: | 20mg/2ml, 80mg/8ml & 160mg/16ml |
| Composition: | Gemcitabine Hydrochloride Gemcitabine 38 mg/mL concentrate for solution for Infusion |
| Indication: | Treatment of locally advanced or metastatic non-small cell-lung cancer, metastatic adenocarcinoma of the pancreas, invasive bladder cancer, locally recurrent or metastatic breast cancer who have relapsed, recurrent epithelial ovarian carcinoma. |
| Packing: | 1 x 26.3 ml |
| Composition: |
Etoposide Concentrate for Solution for Infusion 20mg/ml |
| Indication: |
Small cell carcinoma of the lung. Acute monocytic and myelomonocytic |
| Packing: | 1’s packing vial – 100mg/5ml |
| Composition: |
Methotrexate Solution for injection 25mg/ml |
| Indication: |
Breast cancer, gestational choriocarcinoma, Acute lymphoblastic (stem cell) |
| Packing: | 50mg / Vials 500mg / Vials 1000mg / Vials
|
| Composition: |
Paclitaxel Concentrate for Solution for Infusion 6mg/ml |
| Indication: |
Ovarian cancer, Breast cancer, Advanced non-small cell lung |
| Packing: | 1 x 100mg/16.7ml Vials 1 vial x 30mg/5ml Vials 1 vial x 260mg/43.4ml Vials 1 vial x 300mg/50ml Vials |
| Composition: |
Doxorubicin Concentrate for Solution for Infusion 2mg/ml |
| Indication: |
Acute leukaemia, Wilms’ tumour, neuroblastoma, |
| Packing: | 1’s packing vial – 200mg/ 100ml; 50mg/25ml, 10mg/5ml |
| Composition: |
(Bleomycin Powder For Solution For |
| Indication: |
Squamous cell carcinoma of the skin, head and neck, oesophagus, larynx, |
| Packing: | 1 vial |
| Composition: |
Capecitabine 150mg Film Coated Tablets |
| Indication: |
Locally advanced or metastatic breast cancer, |
| Packing: | 150mg – 60’s 500mg – 120’s |
| Composition: |
Carboplatin Concentrate for Solution for Infusion 10mg/ml |
| Indication: |
Advanced stage ovarian cancer of epithelial origin. |
| Packing: | 15ml / vial 45ml / vial |
| Composition: |
Irinotecan Concentrate for Solution for |
| Indication: |
Advanced colorectal cancer |
| Packing: | 40mg/2ml (1 vial) 100mg/5ml (1 vial) |
| Composition: |
Imatinib Mesylate Film coated tablets 100mg |
| Indication: |
Chronic Myeloid leukemia, Unresectable GI Stromal tumours (GIST). |
| Packing: | 100mg – 60’s 400mg – 30’s |
| Composition: |
Busulfan Injection mg/ml Concentrate |
| Indication: |
Busulfan is indicated for use in combination with |
| Packing: | 1 vial |
| Composition: | Gemcitabine Powder for Solution for Infusion 200 mg/vialGemcitabine Powder for Solution for Infusion 1000 mg/vial |
| Indication: | First-line treatment of metastatic breast cancer (in combination with paclitaxel) after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were contraindicated. |
| Packing: | 1 x 200mg |
| Composition: | Gemcitabine Powder for Solution for Infusion 200 mg/vial Gemcitabine Powder for Solution for Infusion 1000 mg/vial |
| Indication: | First-line treatment of metastatic breast cancer (in combination with paclitaxel) after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were contraindicated. |
| Packing: | 1 x 1000mg |
| Composition: | Cisplatin Concentrate For Solution For Infusion Bp 50mg/50mL |
| Indication: | Metastatic ovarian cancer, Metastatic testicular tumours, Advanced bladder cancer. |
| Packing: | 1 x 50 ml |
| Composition: | Epirubicin Hydrochloride Powder for Solution for Injection 10mg, 50mg |
| Indication: | Acute leukaemias Lymphoma; Multiple myeloma; Solid tumours, Adjuvant treatment in axillary-node positive breast cancer, Local treatment of bladder carcinoma |
| Packing: | 1 X 5ml, 1 X 25ml |
| Composition: | Docetaxel 20mg/ 0.5ml |
| Indication: | Breast cancer, Ovarian cancer, Prostate cancer & Head and neck cancer |
| Packing: | 1 x 0.5 ml |
| Composition: | Bortezomib 3.5 mg Powder for Solution for Injection |
| Indication: | Indicated for the treatment of patients with multiple myeloma, mantle cell lymphoma. |
| Packing: | 3.5mg/10ml 1 vial |
